Medical Oncology

The medical oncology department at the Canberra Region Cancer Centre (CRCC) focuses on the care, treatment and management of patients with cancer.

The medical oncology department at the Canberra Region Cancer Centre (CRCC) focuses on the care, treatment and management of patients with cancer.

This includes managing solid tumours from various cancers through the provision of chemotherapy and supportive care in a multidisciplinary environment.

Our outpatient clinics take place at a number of locations in Canberra and rural NSW. The main treatment location is the CRCC. Specialist outpatient clinics are held every day.

Please call the cancer central access number for more information on 02 5124 8444.

Refer a patient

Patients can only access our services with a valid referral to a named specialist from a GP or specialist. Please ensure all results from previous medical tests are included to assist in the triage and assessment of referrals.

You can fax referrals to us on 02 5124 4266.

HealthLink SmartForms eReferrals will be available in September 2019.

Contact HealthLink on 1800 125 036 or email for more information.

Our specialists

Our medical oncology team is made up of various cutting-edge oncology specialists that deliver best practice cancer medicine. Your GP can access a list of our medical oncology staff specialists through the GP Healthnet.

Clinical Trials

BioGrid: BioGrid Federated Database for the Installation and Implementation of a Database Node for Bio21 Molecular Medicine Informatics Model

ALT GIST: A Randomised Phase II Trial of Imatinib alternating with Regorafenib compared to Imatinib alone for the first line treatment advanced gastro-intestinal stromal tumour

ELIMINATE: Oestrogen lowering intervention may increase neoadjuvant therapy efficacy. Randomised Phase II trial of neoadjuvant chemotherapy +/- concurrent aromatase inhibitor endocrine therapy to downstage large oestrogen receptor positive breast cancer

BR.31: A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MED14736 in Completely Resected Non-Small Cell Lung Cancer

PROSPER: A Phase 4, Randomized, Double-Blind, Placebo Controlled Study of Continued Enzalutamide Treatment beyond Progression in Patients with Chemotherapy-Naïve, Metastatic-Castration Resistant Prostate Cancer:

TABITHA: Study of the clinical outcomes and analysis of antiHER2 therapy use in treatment of metastatic HER2 positive breast cancer

Genetic and cellular analysis of autoimmune and inflammatory disease: Investigation of immune modulating cancer treatments

ECHO: A Phase III randomised controlled trial of exercise during chemotherapy for patients commencing first line treatment for ovarian cancer.

Cardiometabolic Risk Factor: The prevalence of weight gain and cardiometabolic disease in women with breast cancer: identifying trends from diagnosis to remission

TRACC: Prospective Study of clinical outcomes and analysis of bevacizumab use in metastatic colorectal cancer: BioGrid Project

A biomarker study to develop a multicomponent diagnostic screen for the detection of circulating tumour cells (CTC) and cancer stem cells (CSC) using peripheral blood

Complete Freund’s Adjuvant: Phase I Study of Complete Freund’s Adjuvant (CFA) in Patients with Refractory and Relapsed Solid Tumours

Lonsurf/Servier: An Open-label early access phase IIIb study of trifluridine / tipiracil (S 95005/TAS-102) in patients with a pretreated metastatic colorectal cancer

Epiaxis 001-0716: A Phase Ib Safety and Pharmacokinetics (PK)/ Pharmacodynamics (PD) Study to Determine the Dosage of Abraxane in Combination with Phenelzine in Metastatic or Inoperable Locally Advanced Breast Cancer

DYNAMIC: Circulating Tumour (ct) DNA Analysis Informing Adjuvant Chemotherapy in Stage II Colorectal Cancer

SAUL: An Open Label, Single Arm, Multicentre, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract. Protocol MO29983.

VERTU: A Randomised Phase II study of VELiparib + Radiotherapy (RT) with adjuvant Temozolomide (TMZ) + veliparib versus standard RT + TMZ followed by TMZ in patients with newly diagnosed glioblastoma (GBM) with Unmethylated O (6)-methylguanine-DNA methyltransferase (MGMT)

INTEGRATE II: A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

ARCHES: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Clinical Research Staff

Dr Yu Jo Chua, Director, Medical Oncology Research Unit

Olive Doig, RN, Clinical Trials Manager.
Anne Ryan, RN, Clinical Trials Coordinator
Suzie Taylor RN, Clinical Trials Coordinator
David Ilchef, Administrative Assistant

Phone (02) 5124 3688.

Collaborative Associates

A/Professor Christine Hemmings RGON, BHB, MBChB, FRCPA, St John of God Pathology, Subiaco WA.

Dr Alesia Ivashkevich, MSc, PhD, Cancer Research Laboratory, Department of Radiation Oncology, Canberra Hospital.

Dr Anneke Blackburn, BSc PhD, John Curtin School of Medical Research

Professor Sudha Rao, BSc PhD, Molecular and Cellular Biology, Centre for Research in Therapeutics Solutions, University of Canberra

A/Professor Kate Pumpa,BSc MSc PhD, Sport and Exercise Science, Faculty of Health, University of Canberra.

Professor Afaf Girgis, Translation Cancer Research Centre, Ingham Insitute for Applied Medical Research, University of NSW.

Research Grants Held

Prof R. Stuart-Harris. Prospective evaluation of cognitive impairment in women receiving adjuvant chemotherapy for early breast cancer. The Canberra Region Medical Foundation

Stuart-Harris R. The Development of a Clinical Palliative Index for the Treatment of Advanced Cancer. The Private Practice Fund, The Canberra Hospital

Stuart-Harris R. Coping Styles and Severity of Toxicity from Adjuvant Chemotherapy for Early Breast Cancer or Colorectal Cancer. Cancer Council ACT.

Yip D. A Cancer Clinical Trials Research Programme in the ACT. Cancer Council ACT.

Yip D, Budge M, Taupin D, Nolan C. Installation and implementation of Bio21:MMIM (Molecular Medicine Informatics Model now known as BioGrid Australia) in Canberra. TCH Radiation Oncology Private Practice Trust Fund.

Haydon A, Zalcberg J, Walpole E, Yip D, Price T, Howard K, Jefford M. Short Course Oncology Therapy- A study of Adjuvant Chemotherapy in Colorectal Cancer by the CACTUS and OCTO Groups. Cancer Australia Priority driven Collaborative Cancer Research Scheme.

Yip D, Dahlstrom J, Jain S, Barry P, Carpenter J, Clarke C. Westmead Millenium Institute, University of Sydney. The Breast Cancer Tissue Bank: establishment of collection site for collection, storage and transfer of human blood and tissue samples in the ACT.

Rao S, Jans D, Forward J, Dahlstrom J, Yip D. Epigenetic regulation by PKC-theta in human breast cancer stem cells. NHMRC Project Grant

Scott R, Balleine R,Clarke C, Dahlstrom J, Forbes J, Marsh D, Pathmanathan N, Simpson P,Yip D, Zeps N.  Extending the strategic importance of the Australian Breast Cancer Tissue Bank to facilitate breast cancer research. National Breast Cancer Foundation National Infrastructure Grant

Identification of Melanoma Circulating Tumour Cells (CTC)/Cancer Stem Cells (CSC) burden and the role of novel epigenetic enzymes in melanoma cancer biology


Our team focuses on research for the advancement of ACT Health’s medical oncology services.

We contribute data to the ACT and southeast NSW Breast Cancer Treatment Group, as well as the national neuroendocrine tumour registry for further study.

We also participate in the ACT CanNET Project that helps link regional and metropolitan cancer services to quality and clinically-effective cancer services.

Our team supports an active clinical trials program and is involved with collaboration research across different areas of oncology. We also conduct many in-house projects.

Please see the Medical Oncology Research page for more information about our research program and publications.


We are an academic unit of the Australian National University (ANU) Medical School and part of the Division of Cancer, Ambulatory and Community Health Support.

Our staff participate in student teaching, examinations, registrar training, curriculum development and supervision of research projects.

Our department has various medical oncology, radiation oncology and palliative care teaching accreditations. We also offer experience in most subspecialties of medical oncology in a multidisciplinary setting.

Advanced trainees have the option to participate in rural outreach clinics in NSW, as well as the Zita Mary Clinic at Calvary Hospital.

Page last updated on: 16 Aug 2019